Mitoxantrone hydrochloride (NSC-310739) in lymphoma. A Southwest Oncology Group study.
The members of the Southwest Oncology Group have treated thirteen patients with Hodgkin's disease and thirty-seven with non-Hodgkin's lymphoma with mitoxantrone on the every three week schedule. While the result (3/13 responses in Hodgkin's; 9/37 responses in non-Hodgkin's lymphoma) is not striking, there is a definite antitumor activity in a very heavily pretreated group of patients. Toxicity was acceptable. Additional trials in lymphoma are planned using mitoxantrone in combination with BCNU.
D000880:Anthraquinones / Q000009:adverse effects / Q000627:therapeutic use*; D004341:Drug Evaluation; D006689:Hodgkin Disease / Q000188:drug therapy*; D006801:Humans; D007263:Infusions, Parenteral; D008223:Lymphoma / Q000188:drug therapy*; D008942:Mitoxantrone
D000880:Anthraquinones; D008942:Mitoxantrone